Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2004, p. 1435-1436, Vol. 48, No. 4
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.4.1435-1436.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors

LETTER
Members of the genus
Leishmania are parasitic protozoans that
infect about two million people per annum (
5), and they are
emerging as serious opportunistic infective agents in human
immunodeficiency virus-infected patients (
4). Malaria parasites
are responsible for 1.5 to 2.7 million deaths annually, primarily
in Africa (
10). The effort to find new antimalarial agents is
still a high priority given the increasing malaria emergency
largely due to multidrug-resistant
Plasmodium falciparum strains.
The histones of
P. falciparum have recently been proposed as
targets for drug treatment of blood stage parasites (
6). They
also play an important role in chromatin remodeling in trypanosomatids,
which include
Leishmania species and trypanosomes (
3).
Apicidin, a cyclic tetrapeptide isolated from Fusarium spp., was reported to block the in vitro development of apicomplexan parasites by inhibiting parasite (including Plasmodium species) histone deacetylase (HDAC) (6). Another HDAC inhibitor, suberoyl bishydroxamic acid, showed an in vivo cytostatic effect against the acute murine malaria Plasmodium berghei, and one round of treatment with the compound failed to select for resistant mutations (1).
Recently, Mai et al. reported a novel series of hydroxamate compounds, namely, 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, acting as HDAC inhibitors in the range of low micromolar-submicromolar concentrations (7, 8). The aim of the present study was to investigate the in vitro antimalarial and antileishmanial activities of lead compound 1 and some analogues (compounds 2 to 10) to identify potential chemical tools with selective toxicity for protozoa.
The antimalarial activity of compounds 1 to 10 (Table 1) was determined in vitro for chloroquine-sensitive (CQS) (D6, Sierra Leone) and chloroquine-resistant (CQR) (W2, Indochina) strains of P. falciparum. Growth of cultures of P. falciparum was determined by a parasite lactate dehydrogenase assay using Malstat reagent (9). Chloroquine was used as the positive control, while dimethyl sulfoxide was tested as the negative control. Suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA), two well-known HDAC inhibitors, were also tested. Antileishmanial activity of compounds 1 to 10 (Table 1) was tested on a transgenic cell line of Leishmania donovani promastigotes expressing firefly luciferase (assay with Steady Glo reagent; Promega, Madison, Wis.) obtained from Dr. Rafael Balana-Fouce, University of Leon, Leon, Spain. Pentamidine was tested as a reference drug together with SAHA and TSA. All the compounds were simultaneously tested for cytotoxicity on Vero (monkey kidney fibroblast) cells by a Neutral Red assay (2).
Among compounds 1 to 10, only compound 7 showed antimalarial
activity against
P. falciparum strains; however, its 50% inhibitor
concentration (IC
50) values were 22- to 100-fold higher than
those of chloroquine and 4.8- to 8.5-fold and 33- to 93-fold
higher than those of SAHA and TSA, respectively. Compounds 1
to 4 showed little
Plasmodium inhibition activity (Table
1).
This biological behavior of compounds 1 to 10 resembles their
corresponding anti-HDAC effect against maize HD2 (compound 7,
IC
50 = 0.1 µM; compounds 1 to 4, IC
50 = 2 to 4 µM;
compounds 5, 6, and 8 to 10, low-level activity or totally inactivity)
(
7,
8), thus confirming an inhibiting action of compound 7 and,
to a lesser extent, of compounds 1 to 4 on parasite HDAC enzymes.
Surprisingly, the majority of compounds 1 to 10 were found endowed with interesting anti-Leishmania activity (in this case, activity not directly related to their anti-HD2 action) (Table 1). Compounds 2 and 3, the most potent of the series, were as active as pentamidine, slightly less potent than TSA, and >10-fold more potent than SAHA. Interestingly, compounds 2 and 3 were less cytotoxic than the reference drugs. Further studies to elucidate the mechanism of anti-Leishmania activity of such derivatives are in progress.

ACKNOWLEDGMENTS
The work was supported by "Progetto Finalizzato Ministero della
Salute 2002" and AIRC 2003 grants (A.M.), by Centers for Disease
Control Cooperative Agreement grants U50-CCU418839 (EIDs) and
UR3-CCU418652 (malaria), and by U.S. Department of Agriculture
Cooperative Agreement grant 58-6408-2-0009 to the National Center
for Natural Products Research (L.A.W. and B.L.T.).

REFERENCES
1 - Andrews, K. T., A. Walduck, M. J. Kelso, D. P. Fairlie, A. Saul, and P. G. Parsons. 2000. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int. J. Parasitol. 30:761-768.[CrossRef][Medline]
2 - Babich, H., and E. Borenfreund. 1991. Cytotoxicity of T2 toxin and its metabolites with the neutral red cell viability assay. Appl. Environ. Microbiol. 57:2101-2103.[Abstract/Free Full Text]
3 - Belli, S. I. 2000. Chromatin remodelling during the life cycle of trypanosomatids. Int. J. Parasitol. 30:679-687.[CrossRef][Medline]
4 - Calza, L., G. Marinacci, R. Manfredi, V. Colangeli, L. Fortunato, and F. Chiodo. 2001. Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report. J. Chemother. 13:653-657.[Medline]
5 - Croft, S. L., and V. Yardley. 2002. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:319-342.[CrossRef][Medline]
6 - Darkin-Rattray, S. J., A. M. Gurnett, and R. W. Myers. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 93:13143-13147.[Abstract/Free Full Text]
7 - Mai, A., S. Massa, R. Ragno, I. Cerbara, F. Jesacher, P. Loidl, and G. Brosch. 2003. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J. Med. Chem. 46:512-524.[CrossRef][Medline]
8 - Mai, A., S. Massa, G. Sbardella, M. Esposito, R. Ragno, G. Nocca, R. Scatena, F. Jesacher, P. Loidl, and G. Brosch. 2002. Binding mode analysis of 3-(4-aroyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J. Med. Chem. 45:1778-1784.[CrossRef][Medline]
9 - Makler, M. T., J. M. Ries, J. A. Williams, J. E. Bancroft, R. C. Piper, B. L. Gibbins, and D. J. Hinriches. 1993. Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am. J. Trop. Med. Hyg. 48:739-741.
10 - Wirth, D. F. 1999. Malaria: a third world disease in need of first world drug development. Annu. Rep. Med. Chem. 34:349-358.
| | | | | |
Antonello Mai* Ilaria Cerbara Sergio Valente
Dipartimento Studi Farmaceutici Università degli Studi di Roma "La Sapienza" P.le Aldo Moro 5 00185 Rome, Italy
Silvio Massa
Dipartimento Farmaco Chimico Tecnologico Università degli Studi di Siena 53100 Siena, Italy
Larry A. Walker Babu L. Tekwani
National Center for Natural Products Research and Department of Pharmacology School of Pharmacy University of Mississippi University, Mississippi 38677-1848
|
| | | | | |
* Phone: 39-649913392, Fax: 39-396491491, E-mail: antonello.mai{at}uniroma1.it
Phone: (662) 915-7882, Fax: (662) 915-7062, E-mail: btekwani{at}olemiss.edu. |
Antimicrobial Agents and Chemotherapy, April 2004, p. 1435-1436, Vol. 48, No. 4
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.4.1435-1436.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Agbor-Enoh, S., Seudieu, C., Davidson, E., Dritschilo, A., Jung, M.
(2009). Novel Inhibitor of Plasmodium Histone Deacetylase That Cures P. berghei-Infected Mice. Antimicrob. Agents Chemother.
53: 1727-1734
[Abstract]
[Full Text]
-
Andrews, K. T., Tran, T. N., Lucke, A. J., Kahnberg, P., Le, G. T., Boyle, G. M., Gardiner, D. L., Skinner-Adams, T. S., Fairlie, D. P.
(2008). Potent Antimalarial Activity of Histone Deacetylase Inhibitor Analogues. Antimicrob. Agents Chemother.
52: 1454-1461
[Abstract]
[Full Text]
-
Cui, L., Miao, J., Cui, L.
(2007). Cytotoxic Effect of Curcumin on Malaria Parasite Plasmodium falciparum: Inhibition of Histone Acetylation and Generation of Reactive Oxygen Species. Antimicrob. Agents Chemother.
51: 488-494
[Abstract]
[Full Text]